Used in clinical research for the treatment of schizophrenia, targeting cognitive impairment associated with the condition. It acts as a selective muscarinic M4 receptor positive allosteric modulator, aiming to improve cognitive and overall functioning in patients. The compound has been investigated in phase 2 trials to evaluate efficacy and safety in adult populations with schizophrenia.